UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $8.81 Million Holdings in Prothena Co. plc (NASDAQ:PRTA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 1,122.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 526,748 shares of the biotechnology company's stock after purchasing an additional 483,673 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.98% of Prothena worth $8,812,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. DCF Advisers LLC lifted its holdings in shares of Prothena by 0.5% during the 2nd quarter. DCF Advisers LLC now owns 107,500 shares of the biotechnology company's stock valued at $2,219,000 after purchasing an additional 500 shares in the last quarter. Signaturefd LLC boosted its position in Prothena by 182.1% during the 2nd quarter. Signaturefd LLC now owns 1,337 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 863 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Prothena by 13.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,236 shares of the biotechnology company's stock worth $211,000 after acquiring an additional 1,186 shares during the last quarter. Pinnacle Associates Ltd. boosted its position in Prothena by 2.3% during the 3rd quarter. Pinnacle Associates Ltd. now owns 125,747 shares of the biotechnology company's stock worth $2,104,000 after acquiring an additional 2,847 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in Prothena by 3.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 86,071 shares of the biotechnology company's stock worth $1,440,000 after acquiring an additional 3,163 shares during the last quarter. Institutional investors own 97.08% of the company's stock.

Prothena Trading Up 2.3 %

Shares of Prothena stock traded up $0.32 on Monday, reaching $14.37. 521,858 shares of the company were exchanged, compared to its average volume of 576,812. Prothena Co. plc has a one year low of $13.22 and a one year high of $41.54. The company has a market capitalization of $773.25 million, a price-to-earnings ratio of -5.79 and a beta of 0.09. The company has a 50-day moving average of $16.20 and a 200 day moving average of $19.49.

Prothena (NASDAQ:PRTA - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share for the quarter, beating analysts' consensus estimates of ($1.18) by $0.08. Prothena had a negative return on equity of 24.19% and a negative net margin of 98.86%. The business had revenue of $0.97 million for the quarter, compared to analysts' expectations of $1.22 million. During the same quarter in the prior year, the business earned $0.38 EPS. The firm's revenue for the quarter was down 98.9% on a year-over-year basis. Analysts predict that Prothena Co. plc will post -2.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on PRTA. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Prothena in a research report on Monday, September 30th. HC Wainwright reaffirmed a "buy" rating and set a $84.00 price target on shares of Prothena in a research report on Wednesday, November 13th. Oppenheimer reduced their price target on Prothena from $66.00 to $62.00 and set an "outperform" rating for the company in a research report on Wednesday, August 14th. StockNews.com downgraded Prothena from a "hold" rating to a "sell" rating in a research report on Tuesday, November 19th. Finally, Bank of America dropped their price objective on Prothena from $33.00 to $31.00 and set a "neutral" rating on the stock in a research note on Tuesday, October 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $61.86.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.